Rheumatology International

, Volume 39, Issue 6, pp 1107–1112 | Cite as

Adalimumab in the treatment of pediatric Behçet’s disease: case-based review

  • Dimitri PoddigheEmail author
  • Zaure Mukusheva
  • Kaisar Dauyey
  • Maikesh Assylbekova
Cases with a Message


Behçet’s disease (BD) is a systemic vasculitis affecting prominently the veins, which is usually diagnosed in adulthood, but can occur in children younger than 16 years in about 4–26% of cases. The therapy is based on several immune-suppressive drugs; in case of inadequate control and/or complications, the biologic therapy with anti-TNF drugs has been successfully used in adults. Here, we reported one pediatric case of BD with systemic (persistent/recurrent high fever), skin and mucosal manifestations (recurrent aphthous stomatitis, anal/penile ulcers, erythema nodosum and papulo-pustules), that were unresponsive to the conventional treatment with steroids and colchicine; however, he was successfully treated with adalimumab. Compared to adult patients, the experience with adalimumab in the treatment of pediatric BD is very limited. Indeed, through a systematic search in the medical literature, we retrieved 4 case reports and 2 case series, describing BD pediatric patients treated with adalimumab, in addition to three clinical studies including some BD children. The analysis and discussion of these available clinical experiences may indicate adalimumab as an effective and safe option to treat several forms of BD, in addition to BD-related chronic uveitis.


Behçet’s disease Adalimumab Pediatric rheumatology 


Author contributions

DP conceived and wrote the article, and provided contribution to the clinical management; ZM and MA cooperated in the clinical management and provided important intellectual contributions; KD cooperated in the literature search and patient’s management.

Compliance with ethical standards

Conflict of interest

The authors have no conflict of interest to declare.

Informed consent

The guardian and the patient provided informed written consent for this publication.


  1. 1.
    Seyahi E (2019) Phenotypes in Behçet’s syndrome. Intern Emerg Med. (Epub ahead of print) Google Scholar
  2. 2.
    Borlu M, Uksal U, Ferahbas A, Evereklioglu C (2006) Clinical features of Behcet’s disease in children. Int J Dermatol 45:713–716CrossRefGoogle Scholar
  3. 3.
    Karincaoglu Y, Borlu M, Toker SC et al (2008) Demographic and clinical properties of juvenile-onset Behçet’s disease: a controlled multicenter study. J Am Acad Dermatol 58:579–584CrossRefGoogle Scholar
  4. 4.
    Yazici H, Ugurlu S, Seyahi E (2012) Behçet’s disease, is it one condition? Clinic Rev Allerg Immunol 43:275–280CrossRefGoogle Scholar
  5. 5.
    Koné-Paut I (2016) Behçet’s disease in children, an overview. Pediatr Rheumatol Online J 14:10CrossRefGoogle Scholar
  6. 6.
    Hatemi G, Silman A, Bang D et al (2008) EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 67:1656–1662CrossRefGoogle Scholar
  7. 7.
    Emmi G, Bettiol A, Silvestri E, Di Scala G, Becatti M, Fiorillo C, Prisco D (2018) Vascular Behçet’s syndrome: an update. Intern Emerg Med. (Epub ahead of print) Google Scholar
  8. 8.
    Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409–1417CrossRefGoogle Scholar
  9. 9.
    Koné-Paut I, Shahram F, Darce-Bello M et al (2016) Consensus classification criteria for paediatric Behçet’s disease from a prospective observational cohort: pEDBD. Ann Rheum Dis 75:958–964CrossRefGoogle Scholar
  10. 10.
    Caso F, Costa L, Rigante D, Lucherini OM et al (2014) Biological treatments in Behçet’s disease: beyond anti-TNF therapy. Mediators Inflamm 2014:107421CrossRefGoogle Scholar
  11. 11.
    Poddighe D, Cavagna L, Brazzelli V, Bruni P, Marseglia GL (2014) A hyper-ferritinemia syndrome evolving in recurrent macrophage activation syndrome, as an onset of amyopathic juvenile dermatomyositis: a challenging clinical case in light of the current diagnostic criteria. Autoimmun Rev 13:1142–1148CrossRefGoogle Scholar
  12. 12.
    Vallet H, Seve P, Biard L et al (2016) Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French uveitis network. Arthritis Rheumatol 68:1522–1530CrossRefGoogle Scholar
  13. 13.
    Calvo-Río V, Blanco R, Beltrán E et al (2014) Anti-TNF-α therapy in patients with refractory uveitis due to Behçet’s disease: a 1-year follow-up study of 124 patients. Rheumatology (Oxford) 53:2223–2231CrossRefGoogle Scholar
  14. 14.
    Vitale A, Emmi G, Lopalco G et al (2017) Adalimumab effectiveness in Behçet’s disease: short and long-term data from a multicenter retrospective observational study. Clin Rheumatol 36:451–455CrossRefGoogle Scholar
  15. 15.
    Tanida S, Inoue N, Kobayashi K et al (2015) Adalimumab for the treatment of Japanese patients with intestinal Behçet’s disease. Clin Gastroenterol Hepatol 13:940–948CrossRefGoogle Scholar
  16. 16.
    Martín-Varillas JL, Calvo-Río V, Beltrán E et al (2018) Successful optimization of adalimumab therapy in refractory uveitis due to Behçet’s disease. Ophthalmology 125:1444–1451CrossRefGoogle Scholar
  17. 17.
    Poddighe D, Romano M, Gattinara M, Gerloni V (2018) Biologics for the treatment of juvenile idiopathic arthritis. Curr Med Chem 25:5860–5893CrossRefGoogle Scholar
  18. 18.
    Gallizzi R, Pidone C, Cantarini L et al (2017) A national cohort study on pediatric Behçet’s disease: cross-sectional data from an Italian registry. Pediatr Rheumatol Online J 15:84CrossRefGoogle Scholar
  19. 19.
    Robinson AB, Gallentine WB, Rabinovich CE (2010) Pediatric neuro-Behçet’s disease responsive to adalimumab. Pediatr Neurol 43:291–293CrossRefGoogle Scholar
  20. 20.
    Interlandi E, Leccese P, Olivieri I, Latanza L (2014) Adalimumab for treatment of severe Behçet’s uveitis: a retrospective long-term follow-up study. Clin Exp Rheumatol 32:S58–S62Google Scholar
  21. 21.
    Pagnini I, Bondi T, Simonini G, Giani T, Marino A, Cimaz R (2015) Successful treatment with canakinumab of a paediatric patient with resistant Behçet’s disease. Rheumatology (Oxford) 54:1327–1328CrossRefGoogle Scholar
  22. 22.
    Marsili M, Marzetti V, Lucantoni M, Lapergola G, Gattorno M, Chiarelli F, Breda L (2016) Autoimmune sensorineural hearing loss as presenting manifestation of paediatric Behçet disease responding to adalimumab: a case report. Ital J Pediatr 42:81CrossRefGoogle Scholar
  23. 23.
    Lim KI, Yang DH, Ryoo E (2017) Behçet’s disease with multiple splenic abscesses in a child. Intest Res 15:422–428CrossRefGoogle Scholar
  24. 24.
    Atienza-Mateo B, Calvo-Río V, Beltrán E et al (2018) Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet’s disease: multicentre retrospective study. Rheumatology (Oxford) 57:856–864CrossRefGoogle Scholar
  25. 25.
    Nanthapisal S, Klein NJ, Ambrose N, Eleftheriou D, Brogan PA (2016) Paediatric Behçet’s disease: a UK tertiary centre experience. Clin Rheumatol 35:2509–2516CrossRefGoogle Scholar
  26. 26.
    Simonini G, Taddio A, Cattalini M et al (2013) Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis. Pediatr Rheumatol Online J 11:16CrossRefGoogle Scholar
  27. 27.
    Deitch I, Amer R, Tomkins-Netzer O, Habot-Wilner Z, Friling R, Neumann R, Kramer M (2018) The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies. Graefes Arch Clin Exp Ophthalmol 256:801–808CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Medicine, School of MedicineNazarbayev UniversityAstanaKazakhstan
  2. 2.Department of Pediatric Rheumatology, National Research Center of Mother and Child HealthUniversity Medical CenterAstanaKazakhstan

Personalised recommendations